Xenon Pharmaceuticals Secures US$747.5M Financing After Phase 3 Success of AZK
Xenon Pharmaceuticals posted positive phase 3 results for its epilepsy candidate azetukalner (AZK), expanded phase 3 trials into major depressive and bipolar disorders, and readied an FDA new drug application. The company also secured a US$747.5 million follow-on financing, the largest R&D-stage biopharma offering in Canadian history.
1. Bloom Burton Award Finalist
Xenon Pharmaceuticals President and CEO Ian Mortimer was named one of three finalists for the 2026 Bloom Burton Award, recognizing exceptional leadership and innovation within Canada’s healthcare industry.
2. Positive Phase 3 Results
The company reported positive phase 3 clinical outcomes for azetukalner (AZK) in adults with focal onset seizures, reinforcing confidence in its novel epilepsy treatment.
3. Expanded Clinical Program
Xenon has broadened its phase 3 pipeline to include major depressive disorder and bipolar depression, positioning the firm to address additional high-value neurological and psychiatric indications.
4. Historic US$747.5M Financing
Xenon closed a US$747.5 million follow-on financing—the largest by an R&D-stage biopharma in Canadian history—boosting resources ahead of its planned FDA new drug application submission.